REVERSING PARKINSONS' DISEASE John Pepper - Cure Parkinson's
REVERSING PARKINSONS' DISEASE John Pepper
![Thal profile image](https://images.hu-production.be/avatars/9a9de9a6-38e9-4940-aff7-cf380bce30ea_small@2x_100x100.jpg)
![Thal profile image](https://images.hu-production.be/avatars/9a9de9a6-38e9-4940-aff7-cf380bce30ea_small@2x_100x100.jpg)
JohnPepper is here
thanks for posting. no matter what one thinks of John Pepper, he is motivating. walking is good for us regardless and fast walking is even better.
I am hard of hearing. What is he saying that's in the brain is it GDN?
Me too right side deaf. Sometimes I go to transcript on YouTube.
GDNF
Glial derived neurotrophic factor
So inspired by this man! He was my hopamine today. Thank you for posting.
GDNF clinical trial offers hope for restoring brain cells damaged in Parkinson’s
parkinsons.org.uk/news/gdnf...
2019. Terminated.
old article but hints of further research
cureparkinsons.org.uk/2019/...
The Bristol-GDNF trial clinical trial did not achieve its primary end point (demonstrating efficacy according to clinical assessments), but there is evidence in the results that suggest the treatment was having an interesting effect in the brain.
“Analysis of brain imaging data collected at the start of the study and the end of the study indicate improvement in dopamine activity only in the brains of participants who received GDNF. This result certainly requires further investigation. Could there be a rationale for a larger dose of GDNF, or longer treatment duration? Might people with milder symptoms benefit more from GDNF?
While there are discussions underway regarding possible future GDNF studies, there are also several ongoing clinical trials that are worth watching very closely. Firstly, there is a clinical trial in Finland focused on a compound very similar to GDNF, called Cerebral Dopamine Neurotrophic Factor (or CDNF). This protein has also demonstrated neuroprotective properties in models of Parkinson’s, and this Finnish clinical trial is delivering CDNF into the brains of people with Parkinson’s using the same delivery CED system as that used in the GDNF trial. The results of the CDNF study (which is being conducted by a biotech company called Herantis) will be made available in 2020.
In addition, there is also a ‘gene therapy’ GDNF clinical trial being conducted in California. Gene therapy involves treating medical conditions with DNA rather than drugs. The DNA is delivered to cells using carefully engineered viruses as vectors which have had all of their disease-causing components removed. The Californian GDNF gene therapy study is testing the use of a virus which ‘infect’ cells in the brain cells with the DNA instructions for making GDNF. These infected cells will then continually produce GDNF. The participants in this study all have Parkinson’s and the ability of this gene therapy version of GDNF to modify the condition will be evaluated.
clinicaltrials.gov/ct2/show...
Gdnf is still of interest but given that its administration in the brain involves at least as much brain surgery as stem cell transplantation I think it is more likely to be used there
Roger Barker explains that at about 9.20 in this talk for no silver bullet
It's also being used in Australian stem cell trials as fertiliser anu.edu.au/news/all-news/in...
WinnieThePoo Not that I doubt Terminated, but I would like to know why. Do you have a link?
There was a bbc documentary about it. Alan Wohne ran the study. Results were mixed and pfizers decision to pull out as sponsor was controversial.cureparkinsons.org.uk/2019/...
WinnieThePoo Thanks,